New pill takes on three tough cancers in early human test
NCT ID NCT06966024
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a first step to see if this approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Oncology, Austin
RECRUITINGAustin, Texas, 78758, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt- Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DCC-2812
What this could lead to
If it works, this could point toward a new treatment option for advanced kidney, bladder, or prostate cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 60 people, so it is primarily checking safety. The drug may not shrink tumors or may cause side effects that limit its use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.